Navigation Links
Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.

Mississauga, Ontario (PRWEB) June 18, 2013

Inflamax Research Inc., a full service CRO specializing in Proof of Concept and Phase I-IV clinical trials, announced today that they will have a strategic alliance with Northern Air Environmental Technologies (NAET), a specialty air conditioning & environmental control company, for the deployment, monitoring, and servicing of mobile Environmental Exposure Chambers (EECs) used in Allergy, Asthma, and Ocular clinical trials.

Inflamax Research has proprietary Next Generation Environmental Exposure Chamber technology and is a world leader in allergy and asthma research. Mobile EECs (mEEC™), a groundbreaking advancement developed by Inflamax Research, allow for the conduct of multi-center allergy and ocular clinical trials and show great promise in furthering allergy and asthma research by allowing study sites to be set up at targeted locations with a high prevalence of specific allergies, rather than having patients commute to a fixed EEC site. Northern Air will work exclusively with Inflamax Research to support mEEC™ multicenter clinical trials in the area of facility and mEEC™ design, construction, and maintenance.

This strategic partnership between Inflamax Research and Northern Air will expedite trial operationalization by contracting the oversight of custom built environmental control units (ECU) and air handling systems to a sole vendor. Northern Air is involved from point of conceptual design to remote deployment, and on-site validation.    

Inflamax Research will create the allergy models and Northern Air Environmental Technologies Inc. will custom-build the ECUs and supervise the air handling systems in Inflamax Research mEEC™. By having Northern Air as an exclusive vendor, Inflamax can focus on conducting the trials while being assured that the environmental control systems are being overseen by industry experts.

“I am pleased to have Northern Air partner with Inflamax Research to provide the best in Environmental Control Systems and importantly to keep them in top operation at all times,” says Dr. Salapatek, President and CSO Inflamax Research. “We have worked together on many projects in the past with Northern Air and are delighted to work with them again. This alliance allows Inflamax Research to continue to provide the best service possible in quality EEC clinical research”.

Brian Barney, President of Northern Air, echoed this positive outlook on the partnership, “Formalizing our relationship to become exclusive partners with Inflamax is the result of Inflamax and Northern Air Principals working together over many years. Inflamax is an innovator in clinical research and EEC technologies and Northern Air is a world leader in environmental control systems. Together, our companies will continue to lead further advancements.”

About Inflamax Research Inc.:

Inflamax conducts single and multi-centre Environmental Exposure Chamber (EEC) and field studies. In addition to Inflamax’s mobile EEC technology (mEEC™) systems which can be positioned globally, Inflamax has six fixed EECs, ranging in patient capacity from 25 to 100 patients at their headquarters in Toronto, Canada. Inflamax’s EECs have been validated for a variety of allergens and environmental conditions including ragweed, grass, dust mite, and tree allergens, and non-allergic provocateurs such as thermal shifts, fragrance, ozone and low humidity conditions such as those utilized in the study of dry eye syndrome.

About Northern Air Environmental Technologies Inc.:

Northern Air Environmental Technologies Inc. is a full service provider of turn-key environmental systems. Northern Air’s range of skills will take a project from raw concept, through detailed design, and construction, and provide clients with a single-sourced solution that truly achieves the overall performance goals of the system. The approach is innovative, utilizing leading edge technology, controls and data-logging, and is based upon over four decades of experience in all aspects of the commercial and industrial sectors.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
2. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
3. Inflamax Research Appoints Dr. Anne Marie Salapatek President & Chief Scientific Officer
4. Inflamax Research Introduces Electronic Patient Data Acquisition Tablet™ (ePDAT)™ for Real-Time PRO Data Collection
5. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
6. Kitware to Develop an Open-Source HPC Design-Analysis Environment for Nuclear Energy Research
7. Invitation to Register: Annual Defense Threat Reduction Agency Basic Research Technical Review
8. New Research On Stuttering Jul 2-3 At Arizona Symposium
9. UCSB researchers identify the mechanisms underlying salt-mediated behaviors in fruit flies
10. DNA Sequencing Market 2013 Developments & 2016 Product Forecasts in New Research Reports at
11. David Julius Wins 2013 Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):